Vitruvian BioMedical, Inc. products

VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine  for the Prevention of Alzheimer`s Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of Alzheimer’s Disease. The vaccine is a gene-based (DNA)  vaccine, which targets ABeta and TAU and is in development for prevention of Alzheimer`s disease (AD). Unlike a traditional vaccine for AD, the DNA vaccine does not contain ABeta or Tau peptide itself but instead contains a piece of the gene coding for the Abeta and Tau protein.